Ludovic Helfgott/LinkedIn
Nov 15, 2025, 15:45
Ludovic Helfgott: Researchers Have Analysed Novo Nordisk Product Data in Obesity and Cardiovascular Disease
Ludovic Helfgott, Executive Vice President, Product and Portfolio Strategy at Novo Nordisk, shared a post on LinkedIn:
“New paper in The Lancet Group today. Researchers have analysed Novo Nordisk product data in obesity and cardiovascular disease and the results suggest that a reduction of major adverse cardiovascular events in people with overweight or obesity is independent of baseline weight and weight loss.
These findings again support our strategy to reduce the risk of cardiovascular events for the hundreds of millions of people living with overweight or obesity and cardiovascular disease and promote their long-term health.”
Stay updated with Hemostasis Today.
-
Oct 21, 2026, 18:13Wolfgang Miesbach: Hereditary Hemorrhagic Telangiectasia An Overlooked Bleeding Disorder
-
Oct 21, 2026, 17:55Gayatri Kotwal։ New Review on Anemia, Pain, and Nutritional Deficiencies in Cancer Patients
-
Oct 21, 2026, 17:40Tetsuzan Ron: Iron Deficiency Without Anemia Clinical Impact and Management
-
Oct 21, 2026, 17:29Amir Hossien Esfandiari։ The Association Between Viral Infections and Aplastic Anemia
-
Oct 21, 2026, 17:16Melissa Hollo: A Meaningful Step Forward for Women’s Health
-
Oct 21, 2026, 17:09Chipili Ng’onga: Have You Ever Seen a Result That Just Didn’t Make Sense?
-
Oct 21, 2026, 16:57Fabrice Cognasse: Celebrating the Next Generation of Platelet Research and Transfusion Medicine
-
Oct 21, 2026, 16:47Christabel Odeta: Treating Pediatric Cancer in Children With Sickle Cell Disease
-
Oct 21, 2026, 16:36Sharlene Haywood: Bringing Multidisciplinary Learning Into Nursing Practice